Zimmer Biomet updates knee surgery partnership, shares under S&P 500 peer scrutiny

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 09:19.

Zimmer Biomet (US98956P1021) remains tied into the National Football League's long-standing health and safety work through the league's house physician, who also serves as a consultant to the orthopedics group per a recent NFL health committee disclosure. This underlines the medtech company's visibility in the US sports medicine market alongside S&P 500 healthcare peers.

What recent disclosures show

The National Football League's Health and Safety Committee lists New York Jets team doctor Dr. Elliot Pellman as a consultant to Zimmer Biomet in its updated conflict-of-interest documentation for league medical advisers. The document highlights commercial ties for committee members with several medical suppliers across orthopedics and imaging.

This committee-level disclosure confirms Zimmer Biomet's continued presence in professional sports medicine, a niche where competitors such as Stryker and Johnson & Johnson also market joint reconstruction and trauma implants. The NFL disclosure sits alongside references to other industry relationships that must be reported under the league's governance rules for medical advisers.

Analyst lens on earnings and peers

Zimmer Biomet shares trade on the New York Stock Exchange under the ZBH ticker and sit within the S&P 500 healthcare cohort, where investors compare the orthopedics group directly with peers such as Stryker and Boston Scientific. Broker commentary in recent weeks has focused on procedure volumes, pricing discipline and robotic-assisted surgery adoption as key earnings drivers for the coming quarters.

Consensus models compiled by market-data services typically track revenue growth in Zimmer Biomet's knees, hips and trauma segments against broader medtech benchmarks, with free-cash-flow conversion and balance-sheet flexibility cited as valuation anchors. Analysts also flag exposure to US and European reimbursement regimes as factors shaping forward guidance scenarios.

How Zimmer Biomet makes money

Zimmer Biomet generates most of its revenue from musculoskeletal healthcare products, with global leadership positions in knee and significant presence in hip reconstruction systems. The portfolio also includes trauma implants, craniomaxillofacial devices, sports medicine solutions and biologics that support bone healing and soft tissue repair.

Where the shares trade today

The Zimmer Biomet shares (US98956P1021) most recently changed hands on the New York Stock Exchange at 87.29 US dollars at the close on 2026-06-22, according to exchange data. This valuation puts the company's equity in line with a mid-cap range within the broader S&P 500 healthcare segment.

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities. All data are based on publicly available sources and may change without notice.